Evidence map›Paper›PMID 29545909›Full record

ArticleOncotarget2018

Symmetry and symmetry breaking in cancer: a foundational approach to the cancer problem.

J James Frost, Kenneth J Pienta, Donald S Coffey

Abstract read
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Devising a divisome for synthetic cells.Nature reviews. Chemistry · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Ten unanswered questions in cancer: "If this is true, what does it imply"?American journal of clinical and experimental urology · 2018
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

J James FrostDepartment of Radiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Kenneth J PientaJames Buchanan Brady Urological Institute at the Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Donald S CoffeyJames Buchanan Brady Urological Institute at the Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Funding

Tumor microvesicle-mediated modulation of the bone microenvironmentP01CA093900 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KELLER, EVAN T · 2004 to 2024
$29.6M
Multidiciplinary Integrative Genomic Approach to Distinguish Lethal from Indolent Prostate Cancer in Men of Europena and African AncestryU01CA196390 · NCI · JOHNS HOPKINS UNIVERSITY · PI DE MARZO, ANGELO MICHAEL, PIENTA, KENNETH J. · 2015 to 2020
$5.8M
Spatiotemporal Regulation of Chk1 in Cell Biology, Cancer Etiology and TherapyR01CA163214 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI ZHANG, YOU-WEI · 2012 to 2016
$1.6M
NCI NIH HHS P01 CA093900NCI NIH HHS R01 CA163214NCI NIH HHS U01 CA196390
6 · The paper itself

Abstract

Symmetry and symmetry breaking concepts from physics and biology are applied to the problem of cancer. Three categories of symmetry breaking in cancer are examined: combinatorial, geometric, and functional. Within these categories, symmetry breaking is examined for relevant cancer features, including epithelial-mesenchymal transition (EMT); tumor heterogeneity; tensegrity; fractal geometric and information structure; functional interaction networks; and network stabilizability and attack tolerance. The new cancer symmetry concepts are relevant to homeostasis loss in cancer and to its origin, spread, treatment and resistance. Symmetry and symmetry breaking could provide a new way of thinking and a pathway to a solution of the cancer problem.

Indexed as

cancercomplexityscale-freesymmetrysymmetry-breaking

Identifiers

PMID29545909
PMCPMC5837760

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.